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OBJECTIVES: Submitting an HTA dossier a cardinal step in gaining market access
for new drugs. While funding decisions lay on an array of criteria a well designed
global value dossier (GVD) will facilitate development of national dossiers. In order
to gain a better understanding of the optimal structure of a GVD we reviewed
differences in requirements and recent changes in countries like Germany and
Spain. METHODS: Country-specific guidelines for HTA submissions and dossiers
submitted in the last 3 years have been scrutinized to identify the key differences
across European agencies (AWMSG, CVZ, DGFPS, G-BA, HAS/CEPS, NCPE, NICE,
SMC, TLV). Criteria reviewed included the guidelines strictness, and the need of
comparative effectiveness, health economic and budget impact evidence.
RESULTS: The majority of agencies reviewed (89%) have a well defined template
but the outline differs markedly between them. Differences relate to the requested
contents (clinical and budgetary outcomes only [33%] vs. a more cost-effectiveness
framework [67%]), and to the perspective from which the evidence is reviewed
(societal [17%] versus national health system or statuary health insurance perspec-
tive [83%]). Additional differences are the preferred type of economic model (cost
utility versus cost per clinical benefit) and budget impact (incremental budget im-
pact versus net costs) and weight given to indirect treatment comparisons when
head-to-head studies are lacking. CONCLUSIONS:Our review illustrates the lack of
standardization of the requirements across European HTAs. This renders the de-
velopment of a GVD easily adaptable to country-specific submissions, a difficult
task. Our review suggests that the GVD should be orchestrated around the needs
for NICE and implemented with the particularities of the different HTAs.
PHP125
AN EARLY ASSESSMENT OF THE GERMAN FEDERAL JOINT COMMISSION
RESOLUTIONS OF ADDITIONAL CLINICAL BENEFIT
McBride D1, Kilburg A1, Mauskopf J2
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA
OBJECTIVES:To provide early assessment of the process for reimbursement of new
drugs by the German Federal Joint Commission (GBA), which assesses “additional
clinical benefit” (ACB) for the new drug compared to an appropriate comparator.
METHODS: A database was created including the decisions by product and indica-
tion. A qualitative and descriptive statistical analysis was performed to examine
the relationship of ACB decisions to comparators, population size and complete-
ness of the submission. RESULTS: The database included data for 20 final resolu-
tions assessing ACB. Different descriptors of ACB have been used by the GBA in the
published resolutions including: “no additional benefit”; “small clinical benefit”;
“indication of additional clinical benefit, not quantifiable”; or “considerable clinical
benefit”. In 8 (40%) of the final resolutions, ACB was not proven, in 5 (25%) submis-
sions ACB was proven for the indicated population, and in 7 (35%) ACB was proven
only in a subset of the indicated population. For 3 of the 5 submissions where ACB
was proven for the indicated population, the resolution was based on the fact that
this was an orphan drug. Lack of data on an appropriate comparator was given as
the reason for the not proven decision for 4 submissions. The dossier was consid-
ered incomplete for 2 submissions. For three drugs, one for hypertension, one for
hypercholesterolemia and one for postoperative ocular inflammation following
cataract extraction, no dossiers were submitted and the products were allocated to
the appropriate reference price group. CONCLUSIONS: With the exception of res-
olutions for orphan drugs, all but two of the early ACB decisions have found proof
of benefit in only a subgroup of the indicated population. Lack of data on an appro-
priate comparator and target patient population was a common reason for a neg-
ative resolution.
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OBJECTIVES: Health economics and outcomes research (HE&OR) have become in-
creasingly important for Dutch policy makers to decide on the content of the stat-
utory insurance package. Pharmaceutical companies have been well developed in
conducting outcomes research and presenting health economics data in order to
access the insurance package, and reimbursement for their products. However,
HE&OR data are not the only objectives for successful reimbursement strategies.
The objective of this study was to analyse reimbursement trajectories in order to
unravel factors for successful market access. METHODS: A qualitative, retrospec-
tive study have been performed from 2008-2011. Period of study: 1999 -2010. In this
study market access trajectories of the three main TNF -blockers, and several
smaller trajectories of pharmaceutical and medical devices companies have been
analysed. Governmental and company documents and value dossiers were studied
and interviews (n19) were held with decision makers of the Ministry, the Health
Insurance Board, physicians, patient organizations, and responsible persons from
the companies. Because the financial reimbursement scheme in the Netherlands
has been changed by January 1st2012, the results are reanalysed and latest results
are added. RESULTS: Within the Dutch health care system, based on a neo-corpo-
ratist structure, many parties are involved in decision making processes. Pharma-
ceutical companies, scientific associations of physicians, and well-developed pa-
tient organizations are being invited to consultations with policy makers and the
Ministry. Our analysis shows that in depth knowledge of Dutch financing scheme
needs to be accompanied with mutual trust and converging goals of the several
parties. Those goals can easiest be converged on patients’ level. CONCLUSIONS:
Although Dutch policy makers are emphasising HE&OR for accessing the insurance
package, our study shows that important arguments for successful market access
are institutional trust and converging goals of the several parties and, from January
1, 2012, in-depth knowledge of the Dutch dedicated DRG-system.
PHP127
REIMBURSEMENT OF ORPHAN DRUGS: WHAT IS THE DIFFERENCE?
Mueller E1, Schmidt E1, Ehreth J2
1Analytica LA-SER International Inc., Loerrach, Germany, 2LA-SER Europe, Paris, France
OBJECTIVES: Orphan drugs are subject to regulatory and reimbursement regula-
tions that differ with respect to application process and necessary documentation.
An orphan drug status granted by the European Commission gives marketing ex-
clusivity in the EU for 10 years after approval. Reimbursement hurdles are also
supposedly lower for orphan drugs in Europe than usually. METHODS: Definition
and assessment process of orphan drugs for reimbursement were reviewed and
analyzed. Differences to other drugs are outlined and reimbursement decisions
presented. RESULTS: The German law on health care reform (AMNOG) imple-
mented in 2011 requires that with market access newly approved products dem-
onstrate their innovation through a reimbursement dossier to avoid reference
group pricing. For orphan drugs, manufacturers must also submit a dossier but the
additional medical benefit is regarded as having been proofed by the market au-
thorization itself. Thus proof of additional benefit does not need to be presented
but information on relevant patient groups and on the extent of this additional
benefit. However, if annual sales of an orphan drug within the statutory health
insurance exceed 50 million EUR, a full assessment is made. For pirfenidone, the
first orphan drug assessed under the new law, IQWiG (Institute for Quality and
Efficiency in Health Care) declined an additional therapeutic benefit but the G-BA
(Joint Federal Committee) did not follow this conclusion in accordance to the law.
In Italy pirfenidone was grouped into the lowest reimbursement class. Unlike Ger-
many, Italy has special funds set aside for orphan drugs, France has an early access
program, and many countries are struggling with how to create a reimbursement
process that reflects the different regulatory provisions for orphans.
CONCLUSIONS: Although orphan drugs are often regarded as unquestioned reim-
burseable, differences in respective processes and assessments exists. Manufac-
turers are requested to build Market Access arguments carefully and expect chal-
lenges in orphan drug indications as well.
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OBJECTIVES: In 2011, Germany’s new health care reform (AMNOG) came into effect
requiring that with market access newly approved products demonstrate their
innovation to avoid reference group pricing. The manufacturer has to submit a
dossier proving additional benefit versus the appropriate comparator recom-
mended by the G-BA (Joint Federal Committee). On request of the G-BA, IQWiG
(Institute for Quality and Efficiency in Health Care) reviews the dossier and per-
forms the benefit assessment. Manufacturers, associations and experts can submit
comments and attend a hearing; thereafter the G-BA publishes its final resolution.
METHODS: Benefit assessments and G-BA decisions to date were reviewed and
analyzed case by case. Differences between IQWiG and G-BA evaluations are out-
lined and consequences depicted. RESULTS: Up to now 32 dossiers have been
submitted, 19 completed the whole process and further 8 will be finally assessed
shortly. About half of the products additional therapeutic benefit was granted al-
lowing price negotiations with the statutory health insurance. Not in all cases did
the G-BA follow IQWiG’s conclusions as for Eribulin and Pirfenidone (an Orphan
drug). The selection of the appropriate comparator treatment was the most con-
troversial issue between G-BA and pharmaceutical companies, followed by ques-
tions about evidence for and interpretation of benefit. Thus for Linagliptin no ad-
ditional benefit against the appropriate comparator is proven according to the G-BA
and the manufacturer challenges the process. Other critical methodology issues
included the definition of patient-relevant endpoints, use of surrogate endpoints,
determination of target patient populations and use of subpopulations.
CONCLUSIONS: Although in its second year, AMNOG is still a learning process for
all parties involved. Before initiating a dossier it is crucial to investigate possible
pitfalls around dossier development. New questions will emerge when it comes to
the assessment of drugs already on the market as it is now planned for DPP-4
inhibitors.
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OBJECTIVES: Exploring the use of population-level epidemiological data (i) within
the reimbursement decision making process, (ii) identifying recommendations and
requirements on that data, and (iii) investigating the role of that data for reim-
bursement decisions as stated in pharmacoeconomic guidelines. METHODS: We
piloted a comparative review of all national pharmacoeconomic guidelines pub-
lished in English (N26 out of 33) available through the ISPOR Website
http://www.ispor.org/PEguidelines/index.asp. RESULTS: The use of population-
level epidemiological data was addressed by 20 guidelines.16 mentioned the use
for economic evaluations, 4 (additionally) for budget impact analyses, and 4 (also)
for broader technology assessments. 14 guidelines provided explicit recommenda-
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